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Background: Previous studies regarding rhythm control in patients with atrial fibrillation (AF) could not sufficiently
demonstrate the efficacy of available anti-arrhythmic drugs. ‘Upstream therapy’ has emerged as a potential strategy
for the prevention and treatment of AF. The use of angiotensin II receptor blockers and statins has been suggested
to decrease new-onset AF, but which remains inadequately explored. This study was designed to examine whether
valsartan or fluvastatin can reduce the risk of non-permanent AF in patients with hypertension.
Methods/design: The VF-HT-AF study is a multicenter, randomized, open-label, four-arm parallel group study with
comparative evaluation of valsartan and fluvastatin as upstream therapies for the treatment of non-permanent AF
complicated by hypertension. The primary outcome measure is change in the development of paroxysmal AF into
persistent or permanent AF, the development of persistent AF to permanent AF, and change in incidence of overall
and persistent AF recurrence, as evaluated by 7-days ambulatory electrocardiograph monitoring (Holter) and
patients’ diaries during 2 years’ follow-up. Secondary outcome measures of this study include the occurrence of: (1)
fatal and nonfatal myocardial infarction; (2) heart failure (New York Heart Association stage III or IV); (3) cardiogenic
shock; (4) serious bleeding necessitating hospitalization; (5) malignant ventricular arrhythmia; (6) revascularization
therapy; (7) radiofrequency catheter ablation of AF; (8) changes of left atrial dimension, as measured by ultrasound
echocardiography; (9) stroke; (10) cardiovascular mortality; and (11) all-cause mortality. A total of 1879 patients will
be investigated from 15 medical centers throughout China to obtain the relevant information.
Discussion: This is the first study in hypertensive patients complicated non-permanent AF in the Chinese population.
Results of this study will inform the use of upstream therapies of AF.
Trial registration: chictr.org, ChiCTR-TRC-12002642
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Atrial fibrillation (AF), the most common clinically sig-
nificant cardiac arrhythmia, is associated with in-
creased mortality and morbidity [1, 2], especially in
hypertensive patients [3]. In general, hypertension is
the most important risk factor for AF. Although much
effort has been put into the development of an effective* Correspondence: tjcardiol@tijmu.edu.cn
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article, unless otherwise stated.pharmacological treatment, several trials conducted in
the USA and Europe proved that existing traditional
anti-arrhythmic drugs failed to improve the prognosis
of patients with AF [4–7].
Several systematic reviews and meta-analyses have con-
firmed anti-arrhythmic efficacy while raising concerns
about adverse events and mortality [8]. In the past few
years, a number of trials investigating upstream therapy
for the prevention of AF have been reported [9]. Upstream
therapies are long-term modulators of atrial remodeling
regarding structure or function, which may changedistributed under the terms of the Creative Commons Attribution 4.0
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renin-angiotensin system (RAS) is an important thera-
peutic target for atrial remodeling. Angiotensin II receptor
blockers (ARBs) have recently been reported to suppress
AF recurrence in both paroxysmal and persistent AF in
selected patients. However, recent placebo-controlled,
double-blind trials with ARBs failed to show convincing
results [10, 11]. Statins, as a well-established secondary
prevention benefit for atherosclerotic coronary artery dis-
ease, are hypothesized to be beneficial against atrial
arrhythmia, yet the data are inconsistent [12–15]. In
addition, there have been little prospective and random-
ized studies to evaluate the effectiveness of upstream
therapeutic strategies in hypertensive patients with non-
permanent AF.
To confirm the effectiveness of ARBs or statins on AF
in hypertensive patients, the Upstream Therapeutic
Strategies of Valsartan and Fluvastatin on Hypertensive
Patients with Non-permanent AF (VF-HT-AF study) will
be conducted, with 1879 participants from 15 centers.
Methods/design
The VF-HT-AF study is designed as a prospective, ran-
domized, open-label, four-arm parallel, and multicenter
study. The objective of the study is to test the hypothesis
that upstream therapy using valsartan or fluvastatin is
more effective in reducing the recurrence of AF and the
progress from non-permanent AF to permanent AF in
hypertensive patients with non-permanent AF, compared
with conventional antihypertensive therapy using dihy-
dropyridine calcium channel blockers (CCBs). This study
will be conducted according to the principles outlined in
the Declaration of Helsinki. Written informed consent
will be obtained from all patients prior to the study. The
study protocol has been approved by the ethics commit-
tee of the Second Hospital of Tianjin Medical University
(Clinical ethical review, 2012, No. 27) as well as other
participating medical centers, which are secondary or
tertiary healthcare providers in China, and should pro-
vide proof of laboratory quality control. The ethical bod-
ies that approved our study in the various centers are listed
in Additional file 1. If there is any amendment to the
protocol, approval must again be sought from the ethics
committee. The study is registered with the Chinese
Clinical Trial Registry (ChiCTR-TRC-12002642). The
protocol design is based on the Consolidated Standards of
Reporting Trials (CONSORT) and Standard Protocol
Items: Recommendations for Interventional Trials (SPIRIT,
see Additional file 2), and study results will be reported
according to these guidelines.
Patient population and entry criteria
Patients enrolled in the study need to meet the inclusive re-
cruited criteria: (1) have hypertension, defined as an averagesystolic blood pressure ≥140 mmHg (1 mm Hg = 0.133
kPa) or a diastolic blood pressure ≥90mmHg (but a systolic
blood pressure <180 mmHg and a diastolic blood
pressure <110 mmHg) at the first visit, or the re-
quirement of any anti-hypertension treatment at en-
rollment; (2) a history of non-permanent AF within 1
year prior to the enrollment, as confirmed by electrocardi-
ography (ECG), and converted to sinus rhythm; (3) have
not taken ARBs or angiotensin-converting enzyme inhibi-
tors (ACEIs) as well as statins in the previous 2 weeks, or
are taking ARBs, ACEIs and statins, but can accept a
2-week washout period; (4) aged 25–79 years; and (5) will-
ing to sign the informed consent form (Additional file 3).
The exclusion criteria are: (1) persistent AF with a
duration ≥1 year or permanent AF; (2) serious left main
coronary artery disease identified by coronary angiog-
raphy; (3) heart failure (New York Heart Association
[NYHA] stage III or IV); (4) acute myocardial infarction
in the previous 3 months; (5) surgical or interventional
indications of valvular heart disease; (6) uncontrolled
thyroid disease (abnormal free T3, free T4, or thyroid
stimulating hormone, or requiring any anti-thyroid treat-
ment at enrollment); (7) serious liver or renal dysfunc-
tion (ALT > 80 U/l, AST > 80 U/l, or creatinine > 132
μmol/l); (8) history of unstable angina pectoris; (9)
stroke or transient ischemic attack within the previous 3
months; (10) poor treatment compliance, such as central
nervous system or mental illness, or a possibility of be-
ing uncooperative in the follow-up period; (11) have
taken ARBs, ACEIs or statins but cannot accept a 2-
week washout period; (12) obvious hyperlipidemia that
must be treated by statins or fibrates; (13) contraindi-
cation of statins or ARBs; (14) pregnancy or the possi-
bility of pregnancy, or breast feeding; and (15) aged
younger than 25 or older than 79 years.Study design
The VF-HT-AF study is a randomized, multicenter, open-
label, and four-arm parallel study to evaluate the effective-
ness of valsartan, fluvastatin or a combination of both on
recurrent AF in hypertensive patients with non-
permanent AF in China. After providing informed con-
sent, patients will be randomly assigned using a computer
system to one of four groups (the valsartan group, the flu-
vastatin plus dihydropyridine CCBs group, the valsartan
plus fluvastatin group, and the dihydropyridine CCBs
group) by the School of Public Health of Tianjin Medical
University, initially in a 1:1:1:1 ratio. Physicians, who
should be qualified medical practitioners, screen and follow
up the patients in hospital outpatient or inpatient clinics.
All patients’ data will be collected using a standard case re-
port form and transmitted to the central database at the
data center. All centers will be regularly monitored for
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will be completed and corrected by queries.
If the candidate patients have not taken ARBs, ACEIs
or statins in the past at least 14 days, they will be dir-
ectly enrolled and randomized. If the candidate patients
have taken ARBs, ACEIs or statins, they will be random-
ized after a 14-day washout period. Baseline data will be
collected after the washout period.
The initial dose of fluvastatin will be 40 mg/day at
night, while valsartan will be prescribed initially at 80
mg/day. The fluvastatin dose will be no less than 40 mg/
day and that of valsartan will be no less than 80 mg/day
during the follow-up period. Blood pressures in each
group must reach the target blood pressure, which is set
at <140/90 mm Hg.
Follow-up
Clinical follow-up using standardized questionnaires will
be performed every 3 months during the 2 years follow-
up period from the assignment of each patient.
The dosages and types of all other anti-hypertensive,
anti-hyperlipidemia, and anti-arrhythmic drugs used
during the follow-up will be recorded for each patient.
Ultrasound echocardiography will be performed before
the patients enter the study and at the end of the follow-
up period. 7-day Holter monitoring will be performed at
the baseline, 6 month, 12 month and at the end of the
follow-up period. Patients’ diaries, cardiac functionFig. 1 Flow-process diagram. BP, blood pressure; ECG, electrocardiography(NYHA classification) and adverse events during the
follow-up period will be collected every 3 months.
Throughout the study, patients should record diaries
when they feel discomfort. Arrhythmia-related symptoms
are self-evaluated or evaluated by 7-day Holter monitor-
ing, which has five poles, is weighted 50 g, 2.0 × 2.7 cm,
and can record ECG for 7 days. The 7-day Holter instru-
ments were manufactured by BORSAM Co. in Shenzhen,
Guangdong Province, China, and provided by the
study’s sponsor, Tianjin Institute of Cardiology, Tianjin,
China. The attending physicians will also record blood
pressure and ECG during each follow-up. Unless neces-
sary, anti-arrhythmic drug therapy will be discontinued
during the study according to the attending physicians’
advice for each patient. The design of the study is
shown in Fig. 1.
Compliance strategy
To maximize subjects’ compliance, first, we will have a
thorough consent process for all participants. We will
explain the schedule, potential side effects of treatment,
and the responsibilities of the subjects in detail. Second,
we will try to prevent dropouts by providing ongoing
support to patients. A direct telephone line set up for
this trial will enable the study team to communicate
with the patients personally. An information sheet will
be given to each participant providing them or their
caregivers with means of urgent contact. Extra visits and
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who feels harmed by the trial protocol. Certainly those
participants in the control group should not experience
any difference in their condition.
Primary outcome measures
The VF-HT-AF study will examine whether fluvastatin or
valsartan has anti-arrhythmic effects on non-permanent
AF, apart from their lipid-lowering and antihypertensive
effects, in comparison with dihydropyridine CCBs. Also, it
will confirm whether a combination of valsartan and
fluvastatin has better effects on non-permanent AF than
either drug alone.
Therefore, the primary outcome measure is the change
in the development of paroxysmal AF into persistent or
permanent AF, the development of persistent AF to per-
manent AF, as well as the change in incidence of overall
and persistent AF recurrence, which will be evaluated by
7-day Holter monitoring and patients’ diaries during the
2-year’s follow-up of the four treatment groups.
Secondary outcome measures
The secondary outcome measures of this study include
the occurrence of: (1) myocardial infarction; (2) heart
failure (NYHA III or IV); (3) cardiogenic shock; (4) ser-
ious bleeding necessitating hospitalization; (5) malignant
ventricular arrhythmia (including ventricular tachycardia
or fibrillation); (6) revascularization therapy (coronary
artery bypass graft or percutaneous coronary interven-
tions); (7) radiofrequency catheter ablation of AF; (8)
changes of left atrial dimension, as measured by ultra-
sound echocardiography; (9) stroke; (10) cardiovascular
mortality; and (11) all-cause mortality.
Definitions
The definitions of AF are made according to 2012
HRS/EHRA/ECAS Expert Consensus [16]. Paroxysmal
AF is defined as recurrent AF (at least two episodes)
that terminates spontaneously within 7 days. Episodes
of AF no more than 48 hours’ duration that are termi-
nated with electrical or pharmacologic cardioversion
should also be classified as paroxysmal AF episodes.
Persistent AF is defined as continuous AF that is sus-
tained beyond 7 days. Episodes of AF lasting more than
48 hours, but less than 7 days, in which a decision is
made to cardiovert AF electrically or pharmacologic-
ally should also be classified as persistent AF episodes.
Permanent AF refers to long-lasting episodes of AF
that could be considered by any evidence as lasting
longer than 1 year, or to a case of AF for which a deci-
sion has been made not to restore or maintain sinus
rhythm by any means, including catheter ablation or sur-
gery. Myocardial infarction is defined as a cardiac tropo-
nin rise accompanied by typical symptoms, pathological Qwaves, ST elevation or depression, or coronary interven-
tion. Heart failure (NYHA III or IV) requires echocardio-
graphic evidence of reduced left ventricular ejection
fraction or a diagnosis of heart failure by a cardiologist.
Cardiogenic shock is defined by sustained hypotension
with tissue hypoperfusion despite adequate left ventricular
filling pressure. Signs of tissue hypoperfusion include
oliguria (<30 ml/hour), cool extremities, and altered level
of consciousness.
Sample size calculation
The primary outcome measure is the change in the de-
velopment of paroxysmal AF into persistent or perman-
ent AF, the development of persistent AF to permanent
AF, as well as the change in incidence of overall and per-
sistent AF recurrence. Power calculations to provide
estimates for the necessary sample size were conducted
concerning the primary outcome measure. The sample
size was estimated based on findings from the 12-month
results of the J-RHYTHM II study [11], in which the in-
cidence of persistent AF is estimated to be 6.8 % lower
in the valsartan group than in the CCBs group. To en-
sure 80 % power at the 5 % significance level, a sample
size of at least 1404 needs to be included. Considering a
rejection rate of 20 %, about 1879 patients need to be
approached.
Data management
All the data will be entered and stored in a password-
protected computer. To ensure high quality of the data,
a double data entry method will be used. A data moni-
toring committee, of which at least two members will be
independent of the research team, will monitor the data
management process regularly. All the data will be fro-
zen and then locked to prevent further editing after the
validation by the data monitoring committee. Only the
data monitoring committee, the study research assistant
and the principal investigator will have access to the
final data set. The protocol and statistical results will be
published in a scientific journal.
Statistical analysis
All analyses will be performed based on the intention-
to-treat principle with differences assumed to be signifi-
cant at a two-sided P value < 0.05.
Baseline characteristics and follow-up information will
be collected for each group through the questionnaire.
Absolute values for each question will be used to calcu-
late the mean value, standard deviation, median value,
percentile, number of cases, and percentages per group.
Statistical significance will be evaluated by analysis of
variance or Kruskal–Wallis rank sum test for continuous
variables and chi-squared test for categorical variables, re-
spectively. Kaplan–Meier curves will be used to describe
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rank test will be performed to compare survival distribu-
tions for the four groups. To adjust for possible baseline
imbalances between groups, a Cox proportional hazards
model will be used. A hazard ratio will be calculated. In
addition, subgroup analyses will be performed corre-
sponding to the nature of the data. All statistical analyses
will be performed using SPSS statistical software (version
17.00, Chicago, IL, USA).
Quality assurance
Steering committee
The intervention of the steering committee includes
general practice training and practice visits, to develop
and monitor the implementation of the protocol. Tele-
phone support is delivered by the intervention team with
assistance from the principle investigators. The quality
of the intervention process will be monitored and as-
sured by a steering committee using multiple strategies,
including a standardized selection, training and perform-
ance assessments of the intervention team, evaluation of
general practice training, records of practice visits kept
by the intervention team, and ongoing feedback by prac-
tice staff on the intervention during the 24-month
period. The steering committee will be supported by a
statistician, who is responsible for ensuring the timely
publication of this study results.
7-day Holter diagnosis committee
This committee will determine the rhythm of the 7-day
Holter ECGs without knowing the patients’ conditions
and will be responsible for the diagnosis of the recorded
7-day Holter ECGs before the analysis of the primary
and secondary outcome measures.
Safety monitoring board
The safety monitoring board will be responsible for
monitoring patient safety and will recommend prema-
ture cessation of the trial should there be an increase in
unpredicted adverse events.
Discussion
Paroxysmal AF often progresses to persistent or perman-
ent AF when the former increases in frequency and dur-
ation, and accounts for approximately 5.5 % of all
patients with paroxysmal AF per year [17]. One consist-
ent fact that emerges from studies is that conventional
anti-arrhythmic agents, such as class I antiarrhythmics,
do not improve survival rates [18], and their efficacy in
preventing progression of paroxysmal AF to persistent
AF is limited because they do not exert any potential
benefits on electrical or structural remodeling, which
contributes to the pathophysiological basis of AF [19].Preventing new-onset and recurrent AF with upstream
therapies is of great interest, but current data are con-
flicting. Further studies are needed to optimize rhythm
control by anti-arrhythmic drugs and targeted catheter
ablation to specific patient populations at an earlier
stage. There is little data on valsartan and fluvastatin
treatment in patients with hypertension and non-
permanent AF.
Stains: fluvastatin
During recent years, statins have emerged as one of the
most effective treatments to reduce the burden of car-
diovascular disease worldwide. Owing to their remark-
ably good safety profile and declining costs, there has
been some interest in the potential use of statins as dir-
ect anti-arrhythmic or anti-inflammatory drugs [20].
Meta-analysis demonstrated that the use of statins was
significantly associated with a decreased risk of AF in
patients with sinus rhythm [12, 15, 21, 22]. Statins could
be considered for patients with intermediate risk factors
[23] as a secondary prevention of AF [22]. These results
provided some evidence for the benefit of statins beyond
their lipid-lowering activity [20].
The potential mechanisms involved in AF reduction
associated with statin therapy are not fully clear. One
possible pathway involves inflammation, which has been
recognized as an accomplice and a potential trigger for
AF [24]. Bellosta et al. [25] have suggested that statins
have pleiotropic properties, and their anti-inflammatory
effects are associated with a reduction in the expression
of cytokines, intercellular adhesion molecules, and inter-
leukins. Statins reduced the incidence of paroxysmal AF
with a concomitant decrease in C-reactive protein levels
[26], which are believed to be a risk factor for AF. Statin
treatment reduced inflammatory biomarkers, which might
also explain a potentially beneficial effect of statins against
AF [27]. More recently, antioxidative actions have been
hypothesized to prevent electrical remodeling [28]. The
administration of statins significantly decreased generation
of reactive oxygen species in vitro and in vivo [29]. Statins
prevented the development of AF by modulating extracel-
lular remodeling. Statins modified extracellular components
by regulating the expression of matrix metalloproteinases
or their inhibitors [30]. Moreover, statins might downregu-
late the RAS and modulate autonomic nervous system-
induced increases in sympathetic activity, which has been
shown to promote atrial remodeling. Other potential mech-
anisms of action include modification of atherosclerotic
plaque [31], improvement of endothelial function [32], and
alteration of membrane fluidity and ion channel conduct-
ance [21].
Some clinical and experimental studies have suggested
the use of statins to protect against AF [33]. However, in-
sufficient data are available to allow the recommendation
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[27] showed that high-dose atorvastatin did not reduce
the recurrence of AF after cardioversion. Lee et al. [35]
have suggested that statin therapy in patients with parox-
ysmal AF might be limited to the prevention of incident
AF, but it does not appear to inhibit the progression of
paroxysmal AF to permanent AF.
Although some studies [36] established diverse results,
they concur that statins are beneficial in decreasing the
frequency of paroxysmal AF. We are, however, unable to
conclude whether a benefit exists with the use of statins
in inhibiting the progression of paroxysmal to persistent
AF, owing in part to the limited data available.
Interestingly, fluvastatin was able to confer benefit,
despite having the lowest potency. An advantage of
fluvastatin is its long-acting formation, which the DE-
CREASE study investigators stated could serves as a
‘bridge’ during the post-operative period, when patients
were not receiving oral medications. For practice to re-
flect clinical trials, atorvastatin would be selected before
percutaneous coronary intervention and coronary artery
bypass graft, whereas fluvastatin would be selected be-
fore noncardiac surgical procedures [13]. Therefore, we
selected fluvastatin as the treatment statin in our study.
Because it is not clear whether the effects of statin use
on AF depend on the underlying lipid levels, we will en-
roll patients without severe hyperlipidemia.
ARBs: valsartan
The VALUE trial [3] found that the incidence of persist-
ent AF was 1.35 % with valsartan and 1.97 % with amlo-
dipine (unadjusted hazard ratio 0.683, 95 % confidence
interval: 0.525–0.889, P = 0.0046). The VALUE trial
results demonstrated that valsartan-based treatment
reduced the development of new-onset AF, particularly
sustained AF in hypertensive patients, compared with
amlodipine-based therapy. These findings suggest that
ARBs might result in greater benefits than calcium an-
tagonists in hypertensive patients at risk of AF. This
leads to the question of whether or not the RAS is an
underlying mechanism that can be targeted to prevent
AF. Several mechanisms have been proposed to explain the
effects of RAS blockade on prevention of AF, including de-
creased atrial stretch, lowered end-diastolic left ventricular
pressure and left atrial pressure, prevention of atrial fibrosis,
modification of sympathetic tone, alteration in potassium
currents and atrial refractoriness, and direct anti-
arrhythmic effects [37–40]. However, a recent J-RHYTHM
II study [11] has found that there were no significant differ-
ences between an ARB (candesartan) and a CCB (amlodi-
pine) in the development of persistent AF in the treatment
of paroxysmal AF associated with hypertension.
Therefore, large-scale, prospective, randomized clinical
trials are urgently needed to establish whether statins orARB bring a similar benefit and are an appropriate
therapeutic option in the hypertensive patients for the
management of AF.
7-day Holter
The Holter monitor has been recently developed, which
can perform ECG continuously without the need for re-
moval during exercise or sleeping. However, the 24-hour
Holter cannot record arrhythmia for longer than one day.
To monitor AF consistently, we used the 7-day Holter
system and patients’ diaries to record AF in a Chinese
population.
The VF-HT-AF study is a prospective, randomized,
open-labeled, multicenter trial designed to provide novel
data necessary to comprehensively assess the efficiency
of valsartan and fluvastatin on AF prevention in patients
with hypertension and non-permanent AF.
Expected implications
The VF-HT-AF study will determine the anti-arrhythmic
effects of the ARB and statin on the recurrence of non-
permanent AF associated with hypertension. It will also
examine the mortality, morbidity, and perpetuation of
the arrhythmia under valsartan, fluvastatin, dihydropiri-
dine CCBs or combined treatment.
In particular, prevention of persistent and permanent
AF would be expected to reduce hospitalization for heart
failure, the incidence of stroke, morbidity, and mortality
in patients with hypertension. This study will provide
data to health care policymakers and the authors of clin-
ical guidelines regarding the appropriate use of upstream
therapy in hypertensive patients with AF and provide di-
rections for future research.
Therefore, the results of this study will emphasize the
role of upstream therapies in the prevention of AF in a
Chinese hypertensive population and assist in the design
of an optimal therapy for such patients.
However, one important limitation that might be
present in this study is that it is an open-label trial,
because we do not have enough funds to make the
drugs in blinded versions. The drugs that the patients
will use in our study are all provided in hospitals or
pharmacies. The patients and doctors will know the
drugs used. Another limitation is that the control
group is not blank, so we do not test the fluvastatin
effect alone. Because the patients in our study are
hypertensive patients, they must, for ethical reasons,
be treated with antihypertensive therapy. We chose the
group receiving dihydropyridine CCBs as the control
group, comparing them with the dihydropyridine CCBs
plus fluvastatin group. If the recurrence of AF in the dihy-
dropyridine CCBs plus fluvastatin group is less than the
dihydropyridine CCBs group, it will be proved that fluvas-
tatin can reduce the probability of non-permanent AF in
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effects of dihydropyridine CCBs plus fluvastatin, but we
have to use antihypertensive drugs.
Trial status
The trial is currently in the recruitment phase.
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